Given the prospective anti-tumorigenic role of MALT1 inhibitor (MI-2), Saba et al. recently investigated ex-vivo efficacy of MI-2 treatment in primary CLL cells including ibrutinib-resistant CLL tumors. This evidence concerns the gene MALT1 and B-cell chronic lymphocytic leukemia.